Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Cyclosporine Market Size And Revenue Outlook Through 2030
The cyclosporine market has experienced rapid growth in recent years. It is projected to expand from $2.98 billion in 2025 to $3.37 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.0%. The growth observed in the past can be attributed to factors such as the increasing number of organ transplant procedures, its proven effectiveness in immune suppression, the rising incidence of autoimmune diseases, early regulatory approvals, and the broader implementation of hospital-based immunotherapy.
The cyclosporine market size is projected to experience substantial growth in the coming years. It is forecast to reach $5.46 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.8%. This expansion during the forecast period is primarily driven by factors such as an increase in chronic autoimmune conditions, a growing burden of ophthalmic diseases, improved transplant survival rates, broader availability of generic medications, and the rising use of outpatient immunosuppressive therapy. Key trends anticipated in this period include the broadening application of cyclosporine in autoimmune disease management, increased adoption of ophthalmic cyclosporine formulations, a surge in demand for long-term immunosuppressive therapies, greater integration into organ transplant maintenance protocols, and the expansion of generic cyclosporine product offerings.
Get A Free Sample Report With In-Depth Market Insights:
Cyclosporine Market Growth Drivers: What’s Behind The Acceleration?
The increasing occurrence of autoimmune diseases is anticipated to boost the expansion of the cyclosporine market in the future. Autoimmune diseases are defined as disorders where the immune system erroneously targets the body’s own cells, leading to inflammation, harm to tissues, and persistent sickness. The rising occurrence of these conditions stems from genetic predisposition, with improvements in genetic testing revealing more people with inherited risks, thus increasing their vulnerability to these disorders. Cyclosporine effectively treats autoimmune diseases by inhibiting T-cell activation, consequently diminishing detrimental immune reactions against healthy tissues in illnesses like rheumatoid arthritis, psoriasis, and lupus. For example, a thorough review released in October 2024 by Signal Transduction and Targeted Therapy, a journal from Nature, a UK-based peer-reviewed scientific publisher, indicated that around 8.4 million individuals globally are affected by rheumatoid arthritis, with its overall incidence rate rising by 2-3% each year; furthermore, utilizing the Markov model approach, the number of affected individuals is projected to be approximately 13.5-17.4 million by 2040. Consequently, the increasing prevalence of autoimmune diseases is propelling the expansion of the cyclosporine market.
Cyclosporine Market Segment Breakdown: Which Categories Lead On Revenue?
The cyclosporine market covered in this report is segmented –
1) By Indication: Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Autoimmune Myasthenia Gravis, Dry Eye, Other Indications
2) By Dosage Form: Capsule, Eye Drops, Liquid Solutions, Creams And Ointments
3) By Route Of Administration: Oral, Topical, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-Users: Hospitals, Homecare, Speciality Centres, Other End-Users
Subsegments:
1) By Transplant Rejection Prophylaxis: Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant, Other Transplants
2) By Rheumatoid Arthritis: Moderate Rheumatoid Arthritis, Severe Rheumatoid Arthritis
3) By Psoriasis: Plaque Psoriasis, Erythrodermic Psoriasis, Guttate Psoriasis, Pustular Psoriasis
4) By Autoimmune Myasthenia Gravis: Generalized Myasthenia Gravis, Ocular Myasthenia Gravis
5) By Dry Eye: Chronic Dry Eye, Severe Dry Eye
6) By Other Indications: Atopic Dermatitis, Uveitis, Nephrotic Syndrome, Inflammatory Bowel Disease (IBD)
Cyclosporine Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies in the cyclosporine market are concentrating on securing regulatory clearances to broaden their product offerings and strengthen their presence in the market. Obtaining regulatory approvals for cyclosporine confirms its safety and effectiveness, which facilitates market entry and boosts confidence among prescribers and patients. For example, in June 2023, Novaliq GmbH, a biopharmaceutical company based in Germany, obtained approval from the U.S. FDA for VEVYE (cyclosporine ophthalmic solution) 0.1%. This distinctive water-free ophthalmic medication was developed for addressing dry eye disease (DED). It represents the first and only cyclosporine-based solution for this condition, demonstrating effectiveness within a mere four weeks. VEVYE incorporates an innovative water-free technology called EyeSol, which improves cyclosporine’s bioavailability and its retention on the ocular surface without requiring preservatives, oils, or surfactants. The solution operates as a calcineurin inhibitor, contributing to the reduction of inflammation linked to dry eye disease.
Cyclosporine Market Leading Players And Competitive Positioning
Major companies operating in the cyclosporine market are Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd, Apotex Inc., Cipla Ltd, Dr. Reddy’s Laboratories Ltd, Lupin Limited, Glenmark Pharmaceuticals Ltd, Taj Pharmaceuticals Limited, Panacea Biotec Ltd, Novaliq GmbH, Simson Pharma Limited, Strides Pharma Science Ltd, AdvaCare Pharma, JoinHub Pharma, Grevis Pharmaceuticals Pvt Ltd, GMT Pharma International, Logos Pharma.
View The Full Cyclosporine Market Report:
Cyclosporine Market Geographic Landscape: Which Region Leads Industry Growth?
Asia-Pacific was the largest region in the cyclosporine market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the cyclosporine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
